CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-01 | Hardiman Roy C. Chief Business & Legal Officer | Returned to the company · Stock Option (Right to Buy) | −206,074 | 0 | ||
| 2024-07-01 | Hardiman Roy C. Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +206,074 | 206,074 | ||
| 2024-07-01 | Hardiman Roy C. Chief Business & Legal Officer | Returned to the company · Stock Option (Right to Buy) | −53,475 | 0 | ||
| 2024-07-01 | Hardiman Roy C. Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +53,475 | 53,475 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company | −213,903 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award | +213,903 | 213,903 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company | −2,994 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award | +2,994 | 2,994 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −42,780 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +42,780 | 42,780 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −171,122 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +171,122 | 171,122 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −11,978 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +11,978 | 11,978 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −30,642 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +30,642 | 30,642 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −206,074 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +206,074 | 206,074 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −53,475 | 0 | ||
| 2024-07-01 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +53,475 | 53,475 |
Page 17 of 21 · 405 trades